Report 67: Part 4b – Rhabdomyolysis – a.k.a., “Jellied Muscle” – After mRNA Gene Therapy Injections
April 14, 2023 • by Robert W. Chandler, MD, MBA
This report is Part 4b in a series. It follows Part 1, “Report 56: Autopsies Reveal Medical Atrocities of Genetic Therapies Being Used Against a Respiratory Virus;” Part 2, “Report 58: Part 2 – “Autopsies Reveal Medical Atrocities of Genetic Therapies Being Used Against a Respiratory Virus;” and Part 3, “Report 61: Part 3 –Ute Krüger, MD, Breast Cancer Specialist, Reveals Increase in Cancers and Occurrences of ‘Turbo Cancers’ Following Genetic Therapy ‘Vaccines’,” and “Report 64: Part 4a – Re-Humanizing Data Using ‘Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series.“
I. Definition: What is Rhabdomyolysis?
Rhabdomyolysis is a process involving the catastrophic breakdown of skeletal or striated muscle with release of muscle components that have a toxic physiologic effect on the whole person and can be difficult to manage medically. A florid case often has a fatal outcome.
https://img.grepmed.com/uploads/9596/diagnosis-treatment-causes-rhabdomyolysis-differential-original.jpeg (Used with permission by the creator, Dr. Rav Singh K.)
Dr. Singh’s graphic illustrates the complexity of rhabdomyolysis. This chart will make more sense if the reader reviews the chart briefly, then reads the information to follow, and then looks at the graphic a second time.
Bhai and Dimachkie have published a worthwhile review of this condition. https://www.uptodate.com/contents/rhabdomyolysis-clinical-manifestations-and-diagnosis
The following is from their review:
- Symptoms and signs — Rhabdomyolysis is characterized clinically by the triad of myalgias, muscle weakness, and red to brown urine due to myoglobinuria. Biochemically, several serum muscle enzymes are elevated, including CK. The degree of muscle pain and other symptoms varies widely.
- Most of the symptoms of rhabdomyolysis are nonspecific.
- Classic triad — The characteristic triad of complaints in rhabdomyolysis is muscle pain, weakness, and dark urine. However, the full triad is observed in only 1 to 10 percent of cases.
- Muscle — When present, muscle symptoms of rhabdomyolysis may develop over hours to days.
- Pain – In hospitalized patients with rhabdomyolysis, muscle pain affects 23 to 80 percent of patients. Muscle pain, when present, is typically most prominent in proximal muscle groups, such as the thighs and shoulders, and in the lower back and calves [2,5]. Other muscle symptoms include stiffness and cramping.
- Weakness – Muscle weakness may be present depending upon the severity of muscle injury and affects 12 to 70 percent of hospitalized patients with rhabdomyolysis. Weakness usually occurs in the same muscle groups affected by pain or swelling, with the proximal legs most frequently involved.
- Swelling – Muscle swelling affects 8 to 52 percent of patients with rhabdomyolysis. When it occurs, detectable swelling in the extremities generally develops with fluid repletion. Swelling is less common on hospital admission. Swelling may be due to either,
- Myoedema, which is nonpitting and is apparent at presentation or develops after rehydration
- Peripheral edema, which is pitting and occurs with rehydration (particularly in patients with Acute Kidney Injury or AKI)
- Limb induration is occasionally present.
- Urine — Dark-colored urine (red to brown, “tea-colored,” “cola-colored”) is one of the classic signs of rhabdomyolysis (see ‘Classic triad’ above), but it occurs in ≤10 percent of cases. Urinalysis is required to distinguish myoglobinuria (from rhabdomyolysis) from hematuria. (See “Urinalysis in the diagnosis of kidney disease” and ‘Urine findings and myoglobinuria’ below.)
- Myoglobin, a heme-containing respiratory protein, is released from damaged muscle in parallel with CK. Myoglobin is a monomer that is not significantly protein bound and is therefore rapidly excreted in the urine, often resulting in the production of red to brown urine. It appears in the urine when the plasma concentration exceeds 1.5 mg/dL. Visible changes in the urine only occur once urine levels exceed from approximately 100 to 300 mg/dL, although it can be detected by the urine (orthotolidine) dipstick at concentrations of only 0.5 to 1 mg/dL.
Enzymes contained in muscle tissue are released that can be measured in a blood sample helping to confirm the diagnosis. Creatine Kinase (CK) is often elevated to extreme levels and can be used to follow the evolution of the process. Creatine phosphokinase (CPK) is also used to identify damage to skeletal muscle:
Summary – CK vs. CPK Blood Test…
Read full story: Report 67: Part 4b – Rhabdomyolysis – a.k.a., “Jellied Muscle” – After mRNA Gene Therapy Injections – DailyClout